{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T03:10:17Z","timestamp":1776309017782,"version":"3.50.1"},"reference-count":42,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:00:00Z","timestamp":1687910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","award":["OA19\/010"],"award-info":[{"award-number":["OA19\/010"]}],"id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","award":["OA18\/016"],"award-info":[{"award-number":["OA18\/016"]}],"id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014851","name":"Fundaci\u00f3n DISA","doi-asserted-by":"publisher","award":["OA19\/010"],"award-info":[{"award-number":["OA19\/010"]}],"id":[{"id":"10.13039\/501100014851","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014851","name":"Fundaci\u00f3n DISA","doi-asserted-by":"publisher","award":["OA18\/016"],"award-info":[{"award-number":["OA18\/016"]}],"id":[{"id":"10.13039\/501100014851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>For chronic myeloid leukemia (CML) patients with a known risk of cardiovascular events (CVE), imatinib is often recommended for first-line tyrosine kinase inhibitor (TKI) treatment rather than a second-generation TKI (2G-TKI) such as nilotinib or dasatinib. To date, very few studies have evaluated the genetic predisposition associated with CVE development on TKI treatment. In this retrospective study of 102 CML patients, 26 CVEs were reported during an average follow-up of over 10 years. Next-generation sequencing identified pathogenic\/likely pathogenic mutations in genes associated with myeloid malignancies in 24.5% of the diagnostic samples analyzed. Patients with a recorded CVE had more myeloid mutations (0.48 vs. 0.14, p = 0.019) and were older (65.1 vs. 55.7 years, p = 0.016). Age \u2265 60 years and receiving a 2G-TKI in first-line were CVE risk factors. The presence of a pathogenic somatic myeloid mutation was an independent risk factor for CVE on any TKI (HR 2.79, p = 0.01), and significantly shortened the CV event-free survival of patients who received first-line imatinib (by 70 months, p = 0.011). Indeed, 62% of patients on imatinib with mutations had a CVE vs. the 19% on imatinib with a mutation and no CVE. In conclusion, myeloid mutations detectable at diagnosis increase CVE risk, particularly for patients on imatinib, and might be considered for first-line TKI choice.<\/jats:p>","DOI":"10.3390\/cancers15133384","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T01:15:47Z","timestamp":1688001347000},"page":"3384","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Presence of Myeloid Mutations in Patients with Chronic Myeloid Leukemia Increases Risk of Cardiovascular Event on Tyrosine Kinase Inhibitor Treatment"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6955-2290","authenticated-orcid":false,"given":"Ruth","family":"Stuckey","sequence":"first","affiliation":[{"name":"Hematology Department, Hospital Universitario de Gran Canaria Dr. Negr\u00edn, 35019 Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adri\u00e1n","family":"Segura-D\u00edaz","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de Gran Canaria Dr. Negr\u00edn, 35019 Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Nieves","family":"S\u00e1ez Perdomo","sequence":"additional","affiliation":[{"name":"Diagn\u00f3stica Longwood, 50011 Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9943-4404","authenticated-orcid":false,"given":"Manuel Mateo","family":"P\u00e9rez Encinas","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Cl\u00ednico Universitario de Santiago de Compostela, 15706 Santiago de Compostela, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f3se David","family":"Gonz\u00e1lez San Miguel","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario Insular de Gran Canaria, 35016 Las Palmas de Gran Canarias, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanira","family":"Florido","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de Gran Canaria Dr. Negr\u00edn, 35019 Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"S\u00e1nchez-Sosa","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de Gran Canaria Dr. Negr\u00edn, 35019 Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Francisco","family":"L\u00f3pez-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de Gran Canaria Dr. Negr\u00edn, 35019 Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4796-1445","authenticated-orcid":false,"given":"Cristina","family":"Bilbao-Sieyro","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de Gran Canaria Dr. Negr\u00edn, 35019 Las Palmas de Gran Canaria, Spain"},{"name":"Morphology Department, Universidad de Las Palmas de Gran Canaria, 35016 Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Teresa","family":"G\u00f3mez-Casares","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de Gran Canaria Dr. Negr\u00edn, 35019 Las Palmas de Gran Canaria, Spain"},{"name":"Department of Medical Sciences, Universidad de Las Palmas de Gran Canaria, 35016 Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","article-title":"Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Deininger","year":"2020","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF01630378","article-title":"The minute chromosome (Phl) in chronic granulocytic leukemia","volume":"8","author":"Nowell","year":"1962","journal-title":"Blut"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/306239a0","article-title":"Localization of the c-ab1 onco-gene adjacent to a translocation break point in chronic myelocytic leukaemia","volume":"306","author":"Heisterkamp","year":"1983","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Na\u00efve Chronic Myeloid Leukemia Patients Trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results from the Randomized BFORE Trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: An international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am. J. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: Final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00277-016-2820-x","article-title":"Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: An expert opinion","volume":"96","author":"Breccia","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1172\/JCI86249","article-title":"Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension","volume":"126","author":"Guignabert","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_14","first-page":"561.e1","article-title":"Cardiovascular management of patients with chronic myeloid leukemia from a multidisciplinary perspective, and proposing action protocol by consensus meeting","volume":"146","year":"2016","journal-title":"Med. Clin."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.2022015853","article-title":"Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia","volume":"140","author":"Duncavage","year":"2022","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2016-04-708560","article-title":"Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy","volume":"129","author":"Kim","year":"2017","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","article-title":"Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease","volume":"132","author":"Branford","year":"2018","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.3324\/haematol.2018.200220","article-title":"Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors","volume":"104","author":"Nteliopoulos","year":"2019","journal-title":"Haematologica"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/bloodadvances.2019000943","article-title":"Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia","volume":"4","author":"Kankainen","year":"2020","journal-title":"Blood Adv."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1038\/s41467-021-23097-w","article-title":"Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia","volume":"12","author":"Ochi","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-022-00667-9","article-title":"Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation","volume":"12","author":"Shanmuganathan","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"744373","DOI":"10.3389\/fonc.2021.744373","article-title":"Somatic Mutations in Oncogenes Are in Chronic Myeloid Leukemia Acquired De Novo via Deregulated Base-Excision Repair and Alternative Non-Homologous End Joining","volume":"11","author":"Curik","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_26","first-page":"1606","article-title":"Clonal hematopoiesis and nonhematologic disorders","volume":"136","author":"Jaiswal","year":"2020","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/ehf2.13897","article-title":"The new HFA\/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity","volume":"9","author":"Madaudo","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1038\/leu.2017.245","article-title":"Nilotinib-induced vasculopathy: Identification of vascular endothelial cells as a primary target site","volume":"31","author":"Hadzijusufovic","year":"2017","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00432-017-2402-x","article-title":"Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis","volume":"143","author":"Giles","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: A retrospective cohort analysis","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/bloodadvances.2018025874","article-title":"Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ajh.24360","article-title":"Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib","volume":"91","author":"Cortes","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.119.044362","article-title":"Genetic Interleukin 6 Signaling Deficiency Attenuates Cardiovascular Risk in Clonal Hematopoiesis","volume":"141","author":"Bick","year":"2020","journal-title":"Circulation"},{"key":"ref_35","unstructured":"Segura-D\u00edaz, A., Stuckey, R., Florido, Y., Sobas, M., \u00c1lvarez-Larr\u00e1n, A., Ferrer-Mar\u00edn, F., P\u00e9rez-Encinas, M., Carre\u00f1o-Tarragona, G., Fox, M.L., and Taz\u00f3n Vega, B. (2023). Presence of DNMT3A\/TET2\/ASXL1 mutations in polycythemia vera patients increases risk of thrombosis independently of age. Blood Adv., accepted."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"72311","DOI":"10.18632\/oncotarget.11100","article-title":"Genetic predisposition and induced pro-inflammatory\/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients","volume":"7","author":"Bocchia","year":"2016","journal-title":"Oncotarget"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hon.2606","article-title":"Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart","volume":"37","author":"Caocci","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1161\/ATVBAHA.119.313353","article-title":"Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events: From Mechanism to Patient Care","volume":"40","author":"Manouchehri","year":"2020","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","article-title":"Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients","volume":"48","author":"Dorer","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2022-162676","article-title":"Somatic Mutations in Myeloid Transcription Factors and in Activated Signaling Pathway, but Not in Epigenetic Modifier Pathway, Predict the Risk of Treatment Failure and Progression to Advanced Phase in Chronic Myeloid Leukemia","volume":"140","author":"Kim","year":"2022","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1161\/ATVBAHA.120.314694","article-title":"Arterial Thrombotic Complications of Tyrosine Kinase Inhibitors","volume":"41","author":"Wu","year":"2021","journal-title":"Arter. Thromb. Vasc. Biol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/13\/3384\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:02:41Z","timestamp":1760126561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/13\/3384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,28]]},"references-count":42,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["cancers15133384"],"URL":"https:\/\/doi.org\/10.3390\/cancers15133384","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,28]]}}}